BAY R3401

• Description:

  BAY R3401 is an orally active glycogen phosphorylase inhibitor that can achieve irreversible and non-selective inhibition of hepatic glycogenolysis. BAY R3401 inhibits glycogenolysis in liver cells, with IC50 values of 27.06 and 52.83 μM in HL-7702 and HepG2 cells, respectively. BAY R3401 can be used for the research of type 2 diabetes[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302

• Target:

  Phosphorylase

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Metabolic Disease

• Smiles:

  O=C (C1=C (C) N (CC) C (COC2=O) =C2C1C3=CC=CC=C3Cl) OC (C) C

• Molecular Formula:

  C20H22ClNO4

• Molecular Weight:

  375.85

• Precautions:

  P264-P270-P330-P501

• References & Citations:

  [1]Zhang L, et al. Design, Synthesis, and Biological Application of Novel Photoaffinity Probes of Dihydropyridine Derivatives, BAY R3401. Molecules. 2019 Jun 28;24 (13) :2394.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  100276-03-7